Chapter 29: Maternity and Newborn Medications

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Usually when we talk about medication administration, there is this underlying expectation of straightforward, almost mechanical math.

Oh, absolutely.

It is comforting in a way, in most fields of medicine, we really like our variables to be isolated and predictable.

Right.

I mean, you have one patient,

you calculate the dose based on their weight or maybe their lab values.

The provider points and says, there is the target.

It is clean.

Right.

One pill, one patient.

Yeah, exactly.

But then you step into the world of maternal newborn pharmacology and suddenly that linear predictable math is just completely broken.

It really is.

You are dealing with a pharmacological landscape where every single intervention is essentially a high stakes GPS system.

Right.

Because one wrong turn, or I guess one wrong dosage, doesn't just impact one patient, it impacts two.

Yes.

It is the absolute definition of clinical double jeopardy.

You are constantly balancing the physiological needs and the safety of the birthing parent against the, well,

the developmental vulnerabilities of the fetus.

So welcome to this deep dive.

Today, we have a very specific mission for you listening.

We are stepping in as your one -on -one tutors to help you completely master chapter 29 from the Saunders Comprehensive Review for the NCLEX -RN examination, the ninth edition.

And this chapter covers maternity and newborn medications.

Exactly.

We are going to walk through the exact order of the chapter,

breaking down the actual why behind the pharmacology,

the pathophysiology and those all important priority setting strategies.

Our goal is to make sure you can provide safe,

effective patient care and obviously, absolutely ace the NCLEX.

So to navigate this high stakes GPS system, we first have to understand how the map itself has been redrawn in recent years.

Right.

So the chapter sets the stage by introducing the FDA's Pregnancy and Lactation Labeling Rule, which is commonly called the PLLR.

I remember the old system, actually.

We historically just had those letter categories, right?

Like A, B, C, D and X.

Yes, the old letter system.

It was treated almost like getting a grade on a test.

Yeah, like A is great, X is terrible.

Exactly.

But that was an oversimplification that honestly often caused unnecessary panic.

So the PLLR removed those pregnancy letter categories entirely.

Oh, wow.

So they are just gone.

They are gone.

The shift here is toward nuance and context.

Instead of a single letter, the PLLR now mandates detailed narrative information on the risks and benefits of using medications during pregnancy and lactation.

Okay.

So it is about treating the provider and the pregnant client like adults who can make informed decisions together rather than just blindly avoiding medications out of fear.

That is the exact clinical philosophy driving the change.

Yeah.

Because sometimes, I mean, pregnant client needs a medication to survive and deterring them from taking it because of a scary letter grade could be way more dangerous than the drug itself.

Right.

It is all about contextual safety.

Okay, let's apply that idea of safety to our first major clinical scenario.

Sometimes, you know, the body jumps the gun and tries to start the delivery process way too early.

And that is a scary situation.

Totally.

So to understand how we intervene, we have to look at medications that act as the brakes on labor.

We call these tocolytics.

Right.

So tocolytics produce uterine relaxation.

They essentially suppress uterine activity to halt preterm labor.

Okay.

But as with everything in maternal newborn care, we really have to look at the whole picture.

There are strict contra indications here.

Meaning times we absolutely should not hit the brakes.

Exactly.

We cannot try to stop labor if the client has severe preeclampsia, active vaginal bleeding, or if there is a fetal contraindication.

Likewise.

Like if the gestational age is already greater than 37 weeks or if cervical dilation is already greater than four centimeters.

Makes sense.

I mean, if the train has already left the station and is speeding down the track or if the uterine environment is too dangerous to keep the baby inside, we don't hit the brakes.

Right.

We just let labor happen.

But if we can intervene, the chapter highlights a few specific medications.

Let's look at indomethacin first.

It is an NSAID, but the text is very clear on this.

We only use it for less than 48 hours.

Yes.

And we absolutely avoid it past 32 weeks of pregnancy.

Right.

So why is that 32 week mark the point of no return?

Well, this comes down to some really fascinating fetal pathophysiology.

Indomethacin works by preventing the body from releasing prostaglandins, which normally cause contractions.

Okay.

So less prostaglandins equals fewer contractions.

Exactly.

However, in the fetus, those same prostaglandins serve a completely different vital purpose.

They actually keep a specialized blood vessel called the ductus arteriosus open.

Oh, right.

Because the fetus isn't breathing air yet.

They get their oxygenated blood from the placenta.

So they need bypass around their own lungs.

Correct.

The ductus arteriosus is that bypass.

If we give indomethacin past 32 weeks, or we give it for too long, we risk premature closure of that bypass while the fetus is still in the uterus.

Which sounds incredibly life threatening.

It is.

Furthermore, indomethacin reduces fetal urine output.

Wait, fetal urine output.

Why does that matter?

Because fetal urine makes up a very large part of the amniotic fluid.

So reducing it can lead to severely decreased amniotic fluid levels, which is known as oligohydromyos.

Wow.

Okay.

So we have to monitor that incredibly closely with ultrasounds.

Another tocolytic listed is nefetapine, which is a calcium channel blocker.

Yes.

But I really want to spend some serious time on the heavyweight, which is magnesium sulfate.

This drug is heavily tested on the NCLEX.

I always try to visualize magnesium sulfate as like a dimmer switch on the central nervous system.

That analogy works perfectly.

It is a central nervous system depressant and an anti -seizure medication that also happens to cause smooth muscle relaxation.

Okay.

And while it can be used to halt preterm labor, its primary and most critical use is to prevent and control seizures in clients with preeclampsia.

But because it is a dimmer switch, our biggest nursing priority is making sure we don't turn the lights out completely.

Exactly.

You do not want to overdo it.

Yeah.

So the target therapeutic range for magnesium sulfate is 4 to 7 .5 mEq per liter.

What does it look like clinically if we overshoot that and hit toxicity?

This is a major safety alert in the text.

You are looking for signs that the nervous system is simply too depressed to function normally.

You will see respirations dropping to 12 breaths per minute or less.

That is low.

It is.

You will also see deep tendon reflexes or DTRs usually checked at the patella becoming severely suppressed or entirely absent.

So we need that patella reflex present before we administer each dose.

Yes.

And crucially,

we must measure urine output.

Right.

Because magnesium is eliminated through the kidneys.

It is basically a plumbing issue.

If the kidneys are not filtering, the sink overflows.

That is a great way to put it.

So if urine output drops below 25 to 30 mL per hour, the magnesium is just building up in the blood and toxicity happens incredibly fast.

Which is why you must always have readily accessible.

Never start a magnesium sulfate infusion without calcium gluconate at the bedside.

Calcium gluconate.

Got it.

Yeah.

It actively antagonizes the central nervous system depression caused by the magnesium.

Here is a thought, though.

If we are using nifedipine and megsulfate and both of them are great at relaxing smooth muscles,

couldn't a provider just order both at the same time?

Like double the effect and really those contractions down?

Well, that is a very logical assumption, which is exactly what makes it a dangerous one.

Oh, really?

Yeah.

The text has a strict safety alert about this exact scenario.

Combining nifedipine and magnesium sulfate is absolutely avoided because both of them are systemic smooth muscle relaxers.

Okay.

So what happens if you combine them?

If you give them together, you will cause severe sudden and dangerous hypotension.

The blood vessels relax so much that the client's blood pressure will just completely crash.

Wow.

Okay.

So we definitely do not mix those.

Let's move to the next phase of the clinical journey.

Let's say we successfully hit the brakes with our tocolytics.

We haven't stopped labor forever, but we've bought ourselves maybe 48 hours.

Right.

We need to use that narrow window of time to prepare this premature fetus for the outside world while simultaneously prepping to manage the birthing parent's pain.

This brings us to corticosteroids, specifically betamethasone and dexamethasone.

Okay.

These are administered via deep intramuscular injection to a client in preterm labor, typically between 28 and 32 weeks of gestation.

And the entire clinical rationale behind this intervention revolves around a substance called surfactant.

Can we break down what surfactant actually does?

I always think of the premature lungs like wet balloons.

Wet balloons.

Yeah.

If there is no surfactant, the inside walls of the tiny air sacs, the alveoli, they just stick together every time the baby exhales.

And trying to inflate a wet sticky balloon takes a massive amount of energy.

That is exactly the physics of it actually.

Surfactant reduces surface tension in the alveoli.

It acts almost like a lubricant, allowing those tiny air sacs to pop open easily and stay open.

So the steroids help with that.

Yes.

These steroid injections artificially accelerate the fetus's production of lung surfactant.

That drastically reduces the severity of respiratory distress syndrome when they are born.

But it is a potent steroid and we are giving it to the birthing parent.

So they are going to experience the side effects.

Yes, sir.

We have to watch for elevated blood glucose, which is incredibly important for diabetic clients.

We also monitor for pulmonary edema and a decreased resistance to infection.

And alongside prepping the fetus, the chapter deeply addresses maternal pain management using opioid analgesics.

Opioids are very effective at relieving moderate to severe labor pain.

But the physiological reality is that they cross the placental barrier.

Which means if a client has been using opioids regularly during pregnancy, that newborn is going to experience withdrawal symptoms once they are severed from that placental blood supply.

Exactly.

We are talking irritability, excessive crying, tremors, hyperactive reflexes, yawning, sneezing.

And in acute settings, to manage severe opioid toxicity,

specifically respiratory depression in the birthing parent,

we rely on the antidote, which is maloxone.

Yes.

It rapidly reverses the opioid toxicity by essentially kicking the opioids off the receptors.

Oh wait, I am trying to think through the chain reaction here.

If a pregnant client has an active documented history of opioid dependency and their respiratory rate drops dangerously low in labor, and we push naloxone as the antidote, aren't we instantly forcing the mother and the baby into a state of severe, abrupt withdrawal?

You have just identified a critical clinical judgment priority.

Yes, naloxone will precipitate immediate and severe withdrawal in opioid dependent clients.

Oh wow, so what do we do?

Well, this is the exact reason why obtaining a thorough medication and substance history before administering an opioid analgesic is essential.

If you know there is a dependency, you must use alternate pain control measures from the very beginning.

Like epidural analgesia.

Exactly, to avoid triggering that crisis altogether.

That is such a vital NCLEX connection assessment must drive the intervention.

Okay, so we have looked at what happens when the body jumps the gun, but what about the opposite scenario?

When the body won't start labor.

Right.

What happens when the baby needs to come out but the body refuses to start the process?

We can't just force a closed door open, you know, we have to unlock it first.

Unlocking the door is a great way to visualize cervical ripening.

The chapter introduces prostaglandins like mesoprostol and dinaprostone.

We use these when the client has a bishop score of four or less.

And just to clarify for everyone, the bishop score is a physical assessment of how ready the cervix is for labor, right?

Yes.

It measures dilation, its placement, which is the thinning of the cervix and how soft it is.

So a score of four or less means the cervix is firm, thick, and closed like a tightly pursed lip.

Exactly, it is not ready.

Prostaglandins soften and efface that cervix, but the administration protocol is very specific.

What are the rules?

The client must void first.

Then they have to lay supine with a lateral tilt or side lying for 30 minutes to two hours after administration to ensure the medication stays in place and is absorbed.

So prostaglandins are basically priming a rusty lock.

And we stop this treatment once the lock is primed, meaning the bishop's score reaches eight or more, or if a strong effective contraction pattern starts on its own.

Right.

But the biggest risk we are monitoring for is uterine tachycystal.

Tachycystal, that sounds bad.

It is hyperstimulation of the uterus.

It is defined as 12 or more uterine contractions in a 20 -minute period without an alteration in the fetal heart rate pattern.

The uterus is contracting so frequently that it never relaxes.

And if it never relaxes, blood flow to the placenta is compromised.

Exactly.

Once that lock is primed, though, we move to the next step, which is oxytocin.

If prostaglandins unlock the door, oxytocin pushes the door open.

It stimulates the smooth muscle of the uterus to increase the force, frequency, and duration of contractions.

And we administer it via an IV pump, piggybacked at the port nearest the point of venous insertion.

The chapter also provides box 29 .3, right?

Which covers calculating an oxytocin drip.

Yes.

Box 29 .3 is important.

While electronic pumps often handle the math safely in modern practice, the NCLEX expects you to know how to convert million units to units.

Right.

It is a foundational formula of the prescribed dose over the available concentration, multiplied by the volume, to calculate the milliliters per hour.

But the real test of clinical reasoning is in the take action box for oxytocin.

This is pure NCLEX gold.

What are the exact steps a nurse must take if they see a non -reassuring fetal heart rate pattern, like late decelerations or absent variability, while oxytocin is running?

Well, late decelerations indicate utero placental insufficiency.

The fetus is not getting enough oxygen during contractions.

This triggers a strict priority sequence.

Okay.

What is step one?

First, you stop the oxytocin infusion immediately.

You have to remove the stressor.

Second, turn the client on their side.

That is to relieve the weight of the heavy uterus off the vena cava, right?

It instantly improves blood flow to the heart, which improves blood flow to the placenta.

Precisely.

Third, you stay with the client and increase the flow rate of the maintenance IV fluid that does not contain the oxytocin.

This expands maternal blood volume.

Got it.

And the last step.

Fourth, administer oxygen at 8 to 10 liters per minute via a snug face mask to maximize the oxygen carried in that blood.

Okay.

Stop the pit, turn the patient, push fluids, give oxygen.

Got it.

So let's fast forward.

The labor was successful.

The baby is out, but the physiological danger isn't over.

We are now in the aftermath.

The uterus needs to clamp down firmly to prevent postpartum hemorrhage.

And we need to manage maternal immune protection.

Yes.

For postpartum hemorrhage, box 29 .4 outlines a few key medications.

First is methylurganovine, which is an ergot alkaloid.

It produces massive firm contractions of the uterus.

But there is a major safety catch there, isn't there?

There is.

It is never administered before the birth of the placenta.

Right.

Because if you clamp the uterus down before the placenta is out, you trap it inside, which leads to massive infection and bleeding.

Absolutely.

I think of methylurganovine as a chemical tourniquet for the uterus.

And because it is a tourniquet, it causes massive arterial vasoconstriction everywhere in the body, which means the pressure in the pipes, the blood pressure is going to skyrocket.

That is why I would hold it for a hypertensive patient, correct?

That is stellar clinical reasoning.

The text explicitly states that checking blood pressure before administering methylurganovine is a priority.

If hypertension is present, the drug is contraindicated.

So what do they use instead?

In that case, a provider might use carboprostrimethamine instead, which is a prostaglandin that also contracts the uterus.

But even carboprost has a severe contraindication.

You cannot give it if the client has asthma because it causes bronchospasm.

Man, it is fascinating how every medication has specific absolute rule out.

It really is.

Let's talk about the immune system.

I have always been fascinated by how the mother's immune system doesn't just attack the fetus, but sometimes it does, right?

Like with the RH factor.

Yes, that is known as isoimmunization.

If an Rh negative mother is carrying an Rh positive fetus and their blood mixes during pregnancy or birth, the mother's immune system sees that Rh protein as a foreign invader.

Okay.

So it builds an army of antibodies to destroy it.

It might not harm the first baby, but if she gets pregnant with another Rh positive baby, those existing antibodies will cross the placenta and attack the fetus's red blood cell.

Which is devastating.

So we use RhoD immune globulin to prevent that.

It essentially coats and hides the fetal blood cells so the mother's immune system never sees them.

To be successful, it is administered at 28 weeks gestation and again within 72 hours after delivery.

But the text notes a very specific caveat.

RhoD immune globulin is of absolutely no benefit if the client has already developed a positive antibody titer to the Rh antigen.

Oh really?

Yes.

It's a preventative shield.

It is not a cure for an existing immune response.

That makes sense.

Once the army is built, you can't hide the invaders anymore.

Okay.

Moving into the final phase.

With the birthing parent stabilized, our nursing interventions shift entirely to the newborn's immediate survival and prepping the whole family for a safe discharge.

This begins with maternal vaccinations, specifically the rubella vaccine, which is given subcutaneously to nonimmune postpartum clients before discharge.

Is there a priority teaching point for that?

Yes, a very strict one.

The client must avoid pregnancy for one to three months post -vaccine as it is a live virus that could harm a developing fetus.

And for newborns themselves, if they were premature and developed respiratory distress syndrome, we give those lung surfactants we talked about earlier, but we give them directly to the newborn intratracheally down into the lungs.

The key nursing intervention.

Do not suction the intratracheal tube for at least two hours after administration or you will literally just vacuum the medication right back out.

Exactly.

Next is eye prophylaxis.

In the US, it is required by law.

We use erythromycin ophthalmic ointment.

Can we explain the mechanism there?

Why every baby?

Because as the newborn passes through the vaginal canal, they are exposed to whatever bacteria are present.

If the parent has an undiagnosed gonorrhea or chlamydia infection, those bacteria can enter the newborn's eyes and cause severe irreversible blindness.

Erythromycin prevents that.

And whatever you do, do not flush the eyes after instilling the ointment.

Right, though we can delay the installation for one hour after birth to facilitate parent newborn eye contact and bonding.

I love that balance of clinical necessity and human connection.

We also give vitamin K.

I like to think of vitamin K as a starter pack for blood clotting while the newborn waits for their own gut microbiome to boot up.

That is the exact physiological mechanism.

Coagulation factors, which stop us from bleeding, are synthesized in the liver, but they depend entirely on vitamin K to be created.

And babies don't have it yet.

Right.

Vitamin K isn't synthesized by the body alone.

It is synthesized by intestinal bacteria.

Since a newborn's gut is completely sterile at birth, they lack those bacteria and are deficient in vitamin K for the first five to eight days of life until their gut colonizes.

So we have to give it to them.

So we give it as an intramuscular injection in the vastus lateralis muscle of the thigh to prevent hemorrhagic disease.

We also use that same vastus lateralis muscle for the hepatitis B vaccine before discharge.

And a crucial note, if the birthing parent is positive for hepatitis B, we have to give the baby the vaccine plus the hepatitis B immune globulin within 12 hours of birth to provide immediate passive immunity.

Finally, before the family leaves, we must discuss contraceptives and fertility medications.

A key educational point for contraceptives is that antibiotics may decrease the effectiveness of oral contraceptives.

So an alternative backup method is needed during the antibiotic course.

And with fertility meds.

With fertility medications, clients need to be educated on the risks of multiple births and ovarian overstimulation syndrome.

Well, we have covered so much ground today.

Let's bring it all home.

Let's look at exactly how the NCLEX will test your clinical reasoning using the practice questions from the end of the chapter.

Good idea.

Let's analyze question one.

It asks, which assessment findings would cause you to immediately discontinue an oxytocin infusion?

Okay.

The options include fatigue, drowsiness, uterine hyperstimulation, late decelerations, and early decelerations.

We know early decelerations are actually a reassuring sign of fetal head compression, and fatigue is totally normal in labor.

But as we discussed with the take action box,

late decelerations indicate utero placental insufficiency.

It is an ominous sign of fetal distress that requires immediately stopping the infusion.

Spot on.

Now consider question two.

A client is receiving magnesium sulfate for preeclampsia.

What findings indicate medication toxicity?

Okay.

What are the options?

The options are 3 plus proteinuria, respirations of 10, presence of deep tendon reflexes, urine output of 20 L's LER, and a serum magnesium level of 4.

Wait, I'm looking at this question.

I see preeclampsia and mag sulfate.

My brain immediately jumps to the 3 plus proteinuria as the worst sign.

Is that the trap?

That is the exact trap the NCLEX sets to test your critical thinking.

Answering this correctly requires separating the disease from the treatment.

3 plus proteinuria is an expected pathological finding for the disease, which is preeclampsia.

Okay.

It is not a sign of toxicity from the medication.

The true signs of magnesium toxicity are related to severe CNS depression respirations dropping to 10, and urine output dropping to 20 mHr, which as we discussed traps the drug in the body.

A magnesium level of 4 is therapeutic and the presence of reflexes is normal.

That is such a crucial distinction.

Disease symptom versus medication side effect.

You have to read what the question is actually asking.

Let's do one more.

Question 5.

Methylurganavine is prescribed for a client with postpartum hemorrhage.

What is the priority assessment before administration?

Uterine tone, blood pressure, amount of lochia, or deep tendon reflexes?

Well, this tests your knowledge of contraindications.

You know, methylurganavine causes severe vasoconstriction.

So applying the foundational ABCs airway, breathing, circulation, blood pressure is the assessment of circulation.

Because this drug can cause severe hypertension,

checking blood pressure is the absolute priority before giving it.

Boom.

It is all about connecting the pharmacology directly to the physiological priority.

And that wraps up our deep dive into maternity content.

As a quick note for your broader study plan, the text transitions next into unit 6, which shifts focus toward pediatric nursing growth, development, and age -appropriate safety.

Which will require an entirely different set of developmental lenses, but the exact same critical thinking skills we have applied here today.

So what does this all mean for you as you prepare to sit for your NCLE -X?

Think back to where we started this conversation.

The FDA shift from the old ABCDX categories to the detailed pregnancy and lactation labeling rule.

That shift was deeply profound for the medical community.

It moved maternal medicine away from simple rote memorization of letter grades and towards detailed narrative risk -benefit analysis.

And I think that perfectly mirrors your journey as a nursing student right now.

You are moving from the rote memorization of facts to developing true nuanced clinical judgment.

You aren't just memorizing that mag sulfate stops contractions.

You understand the exact mechanism of the dimmer switch and why you reach for the calcium gluconate when the respirations hit 10.

Because the math isn't just about weight anymore.

It is about navigating the profound responsibility of two connected lives.

On behalf of the Last Minute Lecture Team, thank you so much for studying with us today.

We wish you ultimate confidence and massive success on your NCLE -X.

You have got this map.

Now go drive.